Biochemical and Biophysical Research Communications
Specific increase of human kallikrein 4 mRNA and protein levels in breast cancer stromal cells
Section snippets
Materials and methods
Patients and sample collection. Primary breast carcinomas tissues were collected surgically from 37 patients at the Val d’Aurelle Cancer Center, Montpellier, France. Clinicopathological data were described in Table 1. The control group was from 14 healthy women who underwent surgery for mammary reduction. Tumor and normal tissues were immediately frozen in liquid nitrogen after surgery and stored at −80 °C. Sera from five cancer patients and five healthy volunteers were stored at −80 °C. Informed
KLK expression in normal and cancerous breast tissues
We analyzed the expression of the 15 KLK genes in 51 tissues from 14 normal and 37 breast cancer patients. In our conditions, the threshold cycle values for KLK5, 13 and 15 mRNA were undetectable. We then compared mRNA expression levels of the other 12 KLK genes using relative quantification by comparative Ct (Table 2). When mRNA expression in tumor tissues was examined, nine KLK mRNAs showed statistically significant lower expression levels in tumors compared to normal breast tissues. There
Discussion
In contrast to the multiple studies examining a small set of KLKs, we quantitatively analyzed the expression pattern of 15 serine proteases in benign and malignant human breast cancer tissues by real-time PCR, in order to evaluate their usefulness as diagnostic tools. We observed a major down-regulation of most KLK genes in breast tumors compared to normal tissues, while KLK4 was shown, for the first time, to be strongly up-regulated in breast cancer tissues. We observed concordant increase of
Acknowledgements
The authors are grateful to Pr H Rochefort for critical reading of the manuscript. The authors are also grateful to Pr P. Rouanet (CRLC Val d’Aurelle, Department of Surgery, Montpellier, France) and Dr F. Bibeau (CRLC Val d’Aurelle, Department of Pathology, Montpellier, France), which provided the breast tissue samples and sera used for this study.
References (36)
- et al.
Identification and characterization of KLK-L4, a new kallikrein-like gene that appears to be down-regulated in breast cancer tissues
J. Biol. Chem.
(2000) - et al.
Cathepsin D: an independent prognostic factor for metastasis of breast cancer
Lancet
(1989) - et al.
Kallikrein-related peptidase 4 (KLK4) initiates intracellular signaling via protease-activated receptors (PARs): KLK4 AND PAR-2 are co-expressed during prostate cancer progression
J. Biol. Chem.
(2008) - et al.
Protease-activated receptor-2 regulates vascular endothelial growth factor expression in MDA-MB-231 cells via MAPK pathways
Biochem. Biophys. Res. Commun.
(2006) - et al.
Proteinase-activated receptors, targets for kallikrein signaling
J. Biol. Chem.
(2006) - et al.
Substrate specificity of human kallikrein 6: salt and glycosaminoglycan activation effects
J. Biol. Chem.
(2006) - et al.
Activation of proteinase-activated receptor-2 by human kallikrein-related peptidases
J. Invest. Dermatol.
(2008) - et al.
Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method
Methods
(2001) - et al.
Biology of prostate-specific antigen
J. Clin. Oncol.
(2003) - et al.
The expanded human kallikrein (KLK) gene family: genomic organisation, tissue-specific expression and potential functions
Biol. Chem.
(2001)
The new human tissue kallikrein gene family: structure, function, and association to disease
Endocr. Rev.
Human tissue kallikreins: physiologic roles and applications in cancer
Mol. Cancer Res.
The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers
Crit. Rev. Clin. Lab. Sci.
The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA
Clin. Chem.
Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma
Clin. Cancer Res.
Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma
Cancer Res.
The emerging roles of human tissue kallikreins in cancer
Nat. Rev. Cancer
Kallikrein 11 expressed in human breast cancer cells releases insulin-like growth factor through degradation of IGFBP-3
Int. J. Oncol.
Cited by (24)
The GNA13-RhoA signaling axis suppresses expression of tumor protective Kallikreins
2016, Cellular SignallingCitation Excerpt :In one study, KLK5, KLK6, KLK10 and KLK12 were reported to be down-regulated in breast cancer tissues [19]. In another study, mRNA levels of nine out of 12 detectable KLK genes namely, KLK1, KLK2, KLK6, KLK7, KLK9, KLK10, KLK11, KLK12 and KLK14, were found to be significantly down-regulated in malignant breast tissues [20]. Parallel down-regulation of KLK5 and KLK7 mRNA levels in breast cancers has also been reported [21,22].
The kallikrein-related peptidase family: Dysregulation and functions during cancer progression
2016, BiochimieCitation Excerpt :Similarly, in almost 100% of gastric cancer datasets, KLK6 and KLK10 were significantly increased, whereas KLK11 was reduced as previously reported [93–95]. KLK4 seemed to be the only KLK clearly upregulated in the breast cancer datasets as already demonstrated at both mRNA and protein levels [96], whereas KLK5-8 and KLK10 were down-regulated in the majority of datasets available. For further details of KLK expression in other malignant tissues please refer to Table 1.
Hypomaturation enamel defects in Klk4 knockout/LacZ knock in mice
2009, Journal of Biological ChemistryRole of Serine Proteases at the Tumor-Stroma Interface
2022, Frontiers in Immunology